Last updated on January 2019

Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

Brief description of study

The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term Naglazyme (galsulfase) treatment; to further characterize the long-term safety of Naglazyme treatment.

Clinical Study Identifier: NCT00214773

Find a site near you

Start Over

Seattle Children's Hospital

Seattle, WA United States
  Connect »

New York University

New York, NY United States
  Connect »

Carolinas Medical Center

Charlotte, NC United States
  Connect »

Children's Health Care

Minneapolis, MN United States
  Connect »

University of Utah Medical Center

Salt Lake City, UT United States
  Connect »

Baton Rouge Clinic

Baton Rouge, LA United States
  Connect »

St. Joseph's Healthcare

Paterson, NJ United States
  Connect »

Children's Mercy Hospital

Kansas City, MO United States
  Connect »

Emory University

Decatur, GA United States
  Connect »

Fullerton Genetic Center

Asheville, NC United States
  Connect »

Tulane University Medical Center

New Orleans, LA United States
  Connect »

Westmead Hospital

Wentworthville, Australia
  Connect »